ABSTRACT Since its identification in 2000, the interest of scientists in the hepatokine fibroblast growth factor (FGF) 21 has tremendously grown, and still remains high, due to a wealth of very robust data documenting this factor's favorable effects on glucose and lipid metabolism in mice. For more than ten years now, intense in vivo and ex vivo experimentation addressed the physiological functions of FGF21 in humans as well as its pathophysiological role and pharmacological effects in human metabolic disease. This work produced a comprehensive collection of data revealing overlaps in FGF21 expression and function but also significant differences between mice and humans that have to be considered before translation from bench to bedside can be successful. This review summarizes what is known about FGF21 in mice and humans with a special focus on this factor's role in glucose and lipid metabolism and in metabolic diseases, such as obesity and type 2 diabetes mellitus. We highlight the discrepancies between mice and humans and try to decipher their underlying reasons. (Endocrine Reviews 38: 468 -488, 2017) W ith a prevalence of~% in adults, type  diabetes mellitus (TD) is the most prominent metabolic disease worldwide (World Health Organization fact sheet on diabetes at http://www.who. int/mediacentre/factsheets/fs/en). The hallmark of the disease, that is, hyperglycemia, results from insulin resistance of liver, skeletal muscle, adipose tissue, and brain and a concomitant failure of pancreatic b-cells to compensate for this resistance by increased insulin secretion (). Current therapeutic options aim at reducing insulin resistance (metformin, thiazolidinediones), enhancing insulin secretion (sulfonylureas, meglitinides, dipeptidyl peptidase IV inhibitors, incretin mimetics), or excreting glucose via the urine (sodium/glucose cotransporter  inhibitors), but a progressive loss of b-cell function and mass is often observed (). Eventually, the ultima ratio to normalize blood glucose is the replacement of endogenous insulin by injection of human recombinant insulin or insulin analogs. New insights into the molecular pathomechanisms behind insulin resistance and b-cell failure point toward a crucial role for a well-balanced humoral crosstalk between metabolically relevant tissues (e.g., adipose, muscle, liver). Highly relevant players and promising targets for novel therapeutic strategies in this crosstalk were recently identified, among them fibroblast growth factor (FGF) (-). FGF is an endocrine factor secreted by liver acting as a metabolic regulator. Interest in the metabolic effects of FGF was aroused by the emergence of FGF as hit in an in vitro assay testing secreted proteins of unknown function for stimulation of glucose uptake in murine T-L adipocytes in an insulin-independent manner (). Based mainly on preclinical studies in mice showing improvements in glucose and lipid metabolism, FGF emerged as an interesting new candidate for TD treatment, REVIEW and several pharmaceutical companies made huge efforts to put this idea into practice. However, the glucose-lowering potential of FGF in humans has been questioned.
W ith a prevalence of~% in adults, type  diabetes mellitus (TD) is the most prominent metabolic disease worldwide (World Health Organization fact sheet on diabetes at http://www.who. int/mediacentre/factsheets/fs/en). The hallmark of the disease, that is, hyperglycemia, results from insulin resistance of liver, skeletal muscle, adipose tissue, and brain and a concomitant failure of pancreatic b-cells to compensate for this resistance by increased insulin secretion (). Current therapeutic options aim at reducing insulin resistance (metformin, thiazolidinediones), enhancing insulin secretion (sulfonylureas, meglitinides, dipeptidyl peptidase IV inhibitors, incretin mimetics), or excreting glucose via the urine (sodium/glucose cotransporter  inhibitors), but a progressive loss of b-cell function and mass is often observed (). Eventually, the ultima ratio to normalize blood glucose is the replacement of endogenous insulin by injection of human recombinant insulin or insulin analogs. New insights into the molecular pathomechanisms behind insulin resistance and b-cell failure point toward a crucial role for a well-balanced humoral crosstalk between metabolically relevant tissues (e.g., adipose, muscle, liver). Highly relevant players and promising targets for novel therapeutic strategies in this crosstalk were recently identified, among them fibroblast growth factor (FGF) (-). FGF is an endocrine factor secreted by liver acting as a metabolic regulator. Interest in the metabolic effects of FGF was aroused by the emergence of FGF as hit in an in vitro assay testing secreted proteins of unknown function for stimulation of glucose uptake in murine T-L adipocytes in an insulin-independent manner (). Based mainly on preclinical studies in mice showing improvements in glucose and lipid metabolism, FGF emerged as an interesting new candidate for TD treatment,
Molecular Biology of FGF21 in Mice and Humans

FGF21 gene and gene products
In , murine and human FGF were identified and characterized at the cDNA level by Nishimura et al. () . The murine gene is located on chromosome , consists of three coding exons, and gives rise to a single transcript that encodes a preprotein of  amino acids (aa), including an N-terminal signal peptide of  aa. The secreted form has an apparent molecular mass of~ kDa ( aa). The human orthologous gene resides on chromosome , likewise consists of three coding exons (and one noncoding 9-flanking exon), and gives rise to two transcripts due to usage of alternative promoters. Both transcripts encode the same preprotein of  aa, including a signal peptide of  aa. Human FGF shares  aa with the murine ortholog (% identity) and the secreted form has an apparent molecular mass of  kDa ( aa).
FGF21 and the FGF superfamily
Depending on the species, between  and  FGF genes were identified in vertebrates (). In mice and humans  genes (FGF to FGF) exist, which can be phylogenetically grouped into eight subfamilies (). Functionally, FGFs may be grouped into three subfamilies: intracellular FGFs (FGF to FGF) that lack a signal peptide, FGFs [FGF (murine ortholog: FGF) and FGF] with low heparin-/heparan sulfate-binding capacities indicating release into circulation and systemic action, and the remaining FGFs with high heparin-/heparan sulfatebinding capacities, thus potentially mainly acting in an autocrine/paracrine manner ().
FGF21 receptors and their signaling
At target sites, FGF binds and activates members of the FGF receptor (FGFR) family of receptor tyrosine kinases. Mammals have seven primary FGFR isoforms (b, c, b, c, b, c, ) (). FGFR activation by FGF in vitro and in vivo is crucially dependent on b-Klotho (KLB), an FGFR-binding single-pass transmembrane protein (-). Accordingly, a clear preference of FGF for FGFRc/KLB and FGFRc/KLB complexes has been demonstrated (, ). Activation of these complexes by FGF leads to a plethora of rapid signaling events [for a review of general FGF signaling, see Ornitz and Itoh () ]. Among these, the hitherto best described events are phosphorylation of FGFR substrate a and subsequent activation of the mitogen-activated protein kinase cascade, including Raf- and extracellular signal-regulated kinases (ERKs)  and  (, , -). Interaction of FGF with FGFR/KLB is very weak and does not induce ERK phosphorylation (, ).
Tissue specificity of FGF21 and FGF21 receptor gene expression In the initial study discovering FGF, Nishimura et al.
() reported predominant expression of the murine FGF gene in liver and lower messenger RNA (mRNA) levels also in thymus. This preliminary view has been modified and several studies have reported, although too a much lower extent, expression of FGF mRNA also in pancreas, testes, gastrointestinal tract, brain, skeletal muscle, brown adipose tissue (BAT), and white adipose tissue (WAT) (, ). In humans, the FGF gene under basal conditions is considered to be nearly exclusively expressed in liver, and weaker signals were shown in the brain () and, according to unpublished results, in the pancreas () (Fig. ) . Because FGFR and FGFR are rather ubiquitously expressed in mice and humans, the target organ selectivity of FGF is probably determined by the restricted tissue expression of KLB: in keeping with a previous report by Ito et · A better understanding of the role of FGF21 in human physiology and pathophysiology will facilitate the translation of experimental findings from bench to bedside · In both mice and humans, FGF21 exerts adverse effects on bone mass and density, and this has to be taken into account in the development of FGF21-based therapeutics adipose tissue (no KLB expression in muscle) (). In humans, major KLB expression sites are, beyond liver and adipose tissue, breast and bone marrow. Only weak expression signals are observed in human pancreas (). It is conceivable that differences at the KLB expression level between mice and humans may contribute to some of the divergent findings regarding the metabolic actions of FGF described for the two species.
FGF21 in the circulation
Serum FGF concentrations measured in chow-fed mice range from . to  ng/mL (, -) depending on the strain tested, the age of the mice, and the assay used. Serum concentrations of healthy humans exhibit marked interindividual variation ranging from  pg/mL to  ng/mL (-).
As to the stability of FGF in blood, only limited information is available for the half-life of human recombinant (nonglycosylated) FGF, with slightly deviating data ranging from  min to  hours in different mice strains, rats, and cynomolgus macaques (, -). Thus, a half-life of , hours can be assumed for human recombinant FGF. The in vivo stability of endogenous glycosylated FGF in animals and humans is currently unknown. However, as glycosylation generally confers relative resistance to proteolysis, we anticipate that the physiologically occurring FGF form has an appreciably longer half-life in the circulation compared with the bacterially produced recombinant protein.
Recently, Zhen et al. () characterized major cleavage events during proteolytic inactivation of human FGF in the circulation: these include two N-terminal cleavage events after proline residues  and  catalyzed by dipeptidyl peptidase IV and/or fibroblast activation protein (FAP) and one C-terminal cleavage event after proline  probably catalyzed by FAP (). As the C terminus is important for KLB binding and overall activity of FGF (, ), inhibitors targeting FAP may increase full-length, active FGF blood concentrations. This, however, remains to be tested.
Regulation of FGF21 in Mice and Humans
In humans, FGF is considered to be nearly exclusively produced by liver, and data from liverspecific knockout animals suggest that circulating FGF in mice mainly derives from liver (). FGF is, however, also expressed in several key metabolic tissues (see "Tissue specificity of FGF and FGF receptor gene expression" ), and certain physiological stimuli and pathological conditions provoke considerable increments in these extrahepatic expression sites that may influence this hormone's circulating levels. Additionally, there may be metabolically relevant roles of locally produced FGF, for example, in pancreas, brain, muscle, or adipose tissue (, ). Nutritional regulation Nutrient deprivation/fasting, lipid intake via suckling, and consumption of ketogenic diets (i.e., a high-fat low-carbohydrate diets designed to simulate the fasting state) result in a several-fold raise of FGF serum levels in mice that seems to be a result of increased blood concentrations of free fatty acids (FFAs) that activated peroxisome proliferator-activated receptor (PPAR)a-dependent FGF gene induction in liver (, -). Contrasting the FGF induction by FFAs in mice, elevation of plasma FFAs in humans does not increase, but rather decreases circulating FGF concentrations, as shown in two larger studies of healthy volunteers during a lipid tolerance test (, ). Furthermore, humans demonstrate a huge interindividual range of FGF levels, and the effects of fasting (up to  hours) on FGF blood concentrations are not consistent, either showing no effect, only modestly increased levels, or even a drop in FGF levels (, , , ). One explanation for this discrepancy between mice and humans might be the overall higher metabolism of mice as compared with humans. Accordingly, elevations of FGF are only seen in humans after prolonged fasting periods of at least  days (, ). In agreement, mice fasted for  hours demonstrate no difference in FGF expression (). Therefore, the physiological role for human FGF in adaptation to starving is still under debate.
Although the contribution to circulating FGF levels is questionable, starvation regulates FGF expression in extrahepatic tissues: gene and protein expressions of FGF in the pancreas are reduced upon fasting in mice (). Pancreatic FGF expression, however, supposedly does not contribute to circulating levels. A recent murine study rather suggested that pancreatic FGF acts in an autocrine/ paracrine manner as a pancreatic secretagogue to prevent endoplasmic reticulum (ER) stress/protein overload (). Human data are still missing. Sugar ingestion (high-carbohydrate diets), in particular fructose, acutely provokes changes in FGF blood levels and hepatic expression in mice and humans (-). Within  hours after fructose ingestion, FGF concentrations raise .-fold in humans (), and after  hour in mice a twofold increase of FGF has been reported, which seems to be dependent on ChREBP (, ). Glucose led only to a modest and delayed increase in FGF levels in humans (). The robust effect of fructose on FGF levels in mice and humans is intriguing. Together with mouse data showing FGF-induced suppression of sugar ingestion () and that a preference for sweets induced by FGF is dependent on KLB expression in the brain (), the findings provide evidence for a novel negative feedback loop along the liver-brain axis that regulates sugar consumption. A similar mechanism by which FGF acts on the reward system in the brain to regulate food intake has now been indicated in humans ().
A ketogenic diet (KD) strongly induces FGF in liver and increases its circulating levels in mice (). In humans (healthy and obese/diabetic), a KD does not increase FGF serum levels (, , ) and even decreases its levels in obese patients when a KD was combined with low calorie intake (). The observation that upon long-term fasting, ketone bodies appear in the circulation days before FGF levels begin to rise () additionally argues against a regulating role for FGF in ketogenesis in humans. One has to consider, however, that KDs used for mouse studies have lower protein content than do control (chow) diets (.% vs .% wt/wt) (, -), whereas human KDs are usually well controlled for adequate protein content and sometimes are even combined with high protein intake (). Accordingly, supplementation of the murine KD with methionine almost completely prevented the KD-induced FGF induction (). Several studies demonstrated that hepatic FGF production is robustly induced by amino acid deprivation and protein restriction, both of which are mediated by the eukaryotic translation initiation factor (eIF)a-activating transcription factor (ATF)-CHOP axis of the ER stress response in mice (, -). Just as in mice, FGF blood levels increase in humans in response to dietary protein restriction (.-fold after  weeks () and approximately twofold after  weeks) (). Although the human FGF gene was identified as a target for ATF in cell culture experiments (), the involvement of ER stress involving the eIFa-ATF pathway in vivo has not yet been addressed in humans. Recently, with a nutritional modeling platform using data of mice that were fed with one of  diets varying in protein, carbohydrate, fat, and total energy density, a major role for low protein intake driving FGF expression/secretion has been demonstrated with a maximal FGF induction when low protein content was coupled to high carbohydrates (). It appears that FGF levels and its metabolic actions are strongly coupled to the macronutrient composition of the mouse diet, an observation that should be considered in human studies where diet cannot be controlled as tight as in murine studies. (, ) demonstrated that circulating glucagon that rises during exercise enhances hepatic FGF production in humans, indicating a muscle-pancreas-liver axis being responsible for elevated FGF blood levels upon exercise.
Hormonal regulation
As mentioned previously, hepatic FGF expression and circulating FGF levels are increased by glucagon (via adenosine 9-monophosphate-activated protein kinase and PPARa) in mice and humans (, ). Additionally, insulin moderately increases the FGF blood concentration in mice under hyperinsulinemic/ euglycemic clamp technique (-). In agreement, human skeletal muscle does express appreciable amounts of FGF under hyperinsulinemia (-). This increased expression, however, does not significantly contribute to circulating FGF levels (, ). Interestingly, human data indicate suppression of FGF secretion from liver by insulin, which contrasts mouse data showing no difference in FGF levels in liver-specific insulin receptor knockout mice (). Growth hormone (GH) acutely increases FGF serum levels (.-fold after  hours, -fold peak at  hours) in mice, but this seems to be dependent on adipose lipolysis (). In healthy humans, GH had no acute effect on serum FGF levels (after  hours) (). In mice, additional hormonal stimuli of hepatic FGF expression include thyroid hormones (via thyroid hormone receptor b, retinoid X receptor, and PPARa) (, ) and glucocorticoids (via glucocorticoid receptor) (). The effect of these hormones on FGF levels in humans has not been addressed in detail so far. No difference in FGF in hyperthyroidism or after treatment with the liver-selective thyroid hormone analog eprotirome argues against regulation of FGF levels by thyroid hormones in humans ().
Circadian rhythm
A circadian rhythmicity of circulating FGF with high levels during the fasting state and low levels during feeding has been reported for both mice and men (, ). Andersen et al. () reported circadian rhythmicity of human FGF blood levels during a -hour fast with peak levels at : AM and nadirs at : AM. As there are three circadian-responsive elements (E-box, D-box, and a retinoic acid receptorrelated receptor-response element site) that are hallmarks of a classical circadian-regulated gene and are located in the FGF promotor (, , ), direct control of FGF levels by the core clock machinery is possible. In primary murine hepatocytes, insulin induced circadian output protein (i.e., E-binding protein ), which is a repressor of the FGF promoter (). Nevertheless, circadian FGF expression in murine liver seems to be dependent on PPARa in mice (), and in humans oscillating FFA levels match those of FGF (). Thus, insulin and FFAs are physiological signals that may explain the circadian rhythmicity of circulating FGF with high levels during the fasting state (during the night) and low levels during feeding (, , ).
Cold exposure
In BAT and WAT, but not in liver, cold exposure and adrenergic signaling potently induce FGF gene expression in mice and humans (-). The pathway of cold-induced FGF induction includes cyclic adenosine monophosphate (cAMP), protein kinase A, p mitogen-activated protein kinase, and ATF (). Notably, some reports show an increase in serum FGF levels indicating that under certain conditions adipose tissue may contribute to circulating levels in mice and humans (, ). No direct mouse and human data are available, but in rats a difference in arteriovenous concentrations of plasma FGF across interscapular BAT has been demonstrated, further arguing for BAT as a source of circulating FGF (). In agreement, BAT of cold-exposed uncoupling protein (UCP) knockout mice is the source of circulating FGF (), and thus at least in rodents, adipose tissue might contribute to circulating levels under distinct conditions.
PPAR agonists
Treatment with PPARg agonists (thiazolidinediones), clinically used as insulin sensitizers, does not alter human FGF blood levels in humans (, , ). In agreement, PPARg agonist-treated mice have increased FGF protein levels in WAT but no elevated circulating levels (). Treatment with PPARaactivating fibrates increases human FGF blood levels, pointing to a role of this FFA-dependent transcription factor in FGF gene induction reminiscent of that in mice, at least in this pharmacological setting (, , , ). Although selective PPARg agonists induce FGF in adipose tissue but not in liver, selective PPARa agonists do this in liver but not in adipose tissue (, ), reflecting the tissue specificity of these PPARs. Although one mouse study demonstrates that PPARg agonist treatment results in FGF secretion of WAT concomitantly with elevations in plasma FGF (), future studies are needed to explore whether and under which condition WAT is contributing to circulating levels in particular in humans. It is certain that WAT-FGF acts locally as an autocrine/paracrine factor in mice and humans.
In summary (Fig. ) , the main expression and secretion site in mice and humans is the liver. Besides the previously-mentioned stimuli, hepatic FGF expression is regulated by bile acids (via farnesoid X receptor) () and dietary supplements/drugs such as all-trans retinoic acid (via retinoic acid receptor b) (), a-lipoic acid (via cAMP response element binding protein H) (), and resveratrol (via SIRT) (, ). This list demonstrates that hepatic FGF expression in mice and humans is under complex nutritional and hormonal control and is regulated by multiple transcription factors in a combinatorial way with a network of nuclear receptors being of central importance. As to the regulation of circulating FGF, mice and humans share the following physiological stimuli: nutrition (protein restriction, fructose ingestion), exercise (via pancreatic insulin and glucagon), and, to a lesser extent, circadian clock machinery.
FGF21 in Metabolic Disease
Several metabolic disorders are associated with increased FGF levels in mice and humans. In the following section, we discuss metabolic diseases that demonstrate altered FGF levels with a special focus on human data. The reason for increased serum FGF in these pathological conditions is largely unknown (potential FGF resistance will be discussed at the end of the section).
Obesity
Genetic and diet-induced murine models of obesity, such as ob/ob and HFD-fed CBL/ mice, display several-fold increased serum FGF concentrations (up to  ng/mL) that are accompanied by increased FGF gene expression in liver and to a lesser extent in WAT (, ). In humans, FGF blood concentrations positively associate with body mass index (BMI) and whole-body, visceral, pericardial, and epicardial fat mass and are elevated in the obese state (, , , , -). Overfeeding-induced gain of weight and body fat result in elevated human FGF concentrations (, ). In contrast, acute and pronounced weight and body fat losses due to bariatric (Roux-en-Y gastric bypass) surgery do not lead to reductions in circulating FGF (, ), showing that adipose tissue is not a source of circulating FGF in humans. Metabolically unhealthy obesity Common obesity can be dissociated into two subtypes: metabolically healthy obesity without serious metabolic complications (~% to %), with the remainder being metabolically unhealthy obesity (MUHO) characterized by insulin resistance, increased visceral fat mass, ectopic fat deposition in skeletal muscle and liver, inflamed adipose tissue and liver, and increased intima-media thickness of the carotid artery (-). Recently, Berti et al. () demonstrated that FGF blood levels are more than twofold higher in MUHO as compared with body fat-matched metabolically healthy obese subjects, and the authors suggested that this reflects an adiposity-independent role of FGF in the metabolic derangements of MUHO. This is in agreement with studies, for example, reporting BMI-and body fat massindependent positive associations of FGF levels with insulin resistance (, ).
Mouse models of obesity-associated diseases, such as nonalcoholic fatty liver disease, chronic hyperglycemia, and atherosclerosis, consistently reveal increased FGF blood levels (-). Also in humans, FGF levels are increased in several obesityassociated disorders and the metabolic syndrome (, , , ).
Fatty liver and diabetes
The strongest BMI-independent determinant of hepatic FGF production and circulating FGF concentrations is liver fat content (-), and fatty liver is a hallmark of MUHO (). Accordingly, FGF blood concentrations are consistently elevated in patients with nonalcoholic fatty liver disease and steatohepatitis (, -, -). With respect to the prominent role of fatty liver in the pathogenesis of TD [for review, see Stefan et al. ()], it is not unexpected that FGF blood levels are increased in prediabetic dysglycemia (, -), TD (, -), gestational diabetes (, ), and diabetic retinopathy (, ). Additionally, in the blood of patients with (diabetic) nephropathy, elevated FGF concentrations were measured, which may derive from reduced glomerular filtration rates (-).
Lipid profile and vascular complications
Higher circulating FGF concentrations associate with atherogenic lipid profiles, that is, increased plasma triglycerides, total and low-density lipoprotein (LDL) cholesterol, and decreased high-density lipoprotein cholesterol (, , , , , , -). Among these lipids, circulating FGF most robustly correlates with plasma triglycerides, possibly reflecting its strong association with hepatosteatosis and steatosis-related increased very-low-density lipoprotein secretion.
The associations of elevated FGF blood levels with metabolic syndrome, increased intima-media thickness, arterial stiffness, and atherosclerotic plaque formation (, -), as well as with coronary artery/heart disease (, , ) and acute myocardial infarction (), argue for a complex, that is, liver fat-dependent and -independent, relationship of this hormone with vascular complications. This is additionally strengthened by the association of FGF with hypertension (, , , , , ) and preeclampsia ().
Bone diseases
In keeping with the inhibitory action of FGF on bone formation in mice (), Hanks et al. () reported an inverse relationship between circulating FGF and bone mineral density measured by dual energy X-ray absorptiometry in humans. Moreover, elevated FGF levels are associated with reduced bone strength and worsened bone microarchitecture (decreased trabecular number and increased trabecular separation in the radius) () and with bone loss in knee osteoarthritis ().
Muscle diseases
In mouse models, manipulations inducing metabolic dysregulation in muscle lead to the induction and release of FGF from muscle: Izumiya et al. () reported that muscle-specific transgenic Akt overexpression increases FGF expression and blood concentrations, providing evidence that musclederived FGF can be of systemic relevance. Mitochondrial myopathy, a stress situation accompanied by Akt activation, is associated with FGF gene induction in skeletal muscle (). Additionally, musclespecific autophagy knockouts (ATG) demonstrate mitochondrial stress/ATF-dependent increased FGF expression in muscle, but not in liver, WAT, or BAT, and an increase in serum FGF levels (). Similar regulation of the FGF gene is seen in heart muscle: fasting and ER stress, with the latter resulting from intracellular triglyceride overload due to wholebody deficiency of adipose triglyceride lipase, provoke marked increases in FGF expression (). Induction of muscular ER stress (evidenced by eIFa and ATF activation) by ectopic expression of uncoupling protein  results in markedly enhanced FGF gene expression in muscle, but not in liver or adipose tissue, and in fivefold higher FGF blood levels even in the absence of myopathy (). Likewise, mice accumulating intramyocellular triglycerides due to skeletal muscle-specific transgenic perilipin  overexpression also exhibit pronounced FGF expression in muscle and concomitantly increased circulating FGF concentrations (). Also, human myopathy (mitochondrial and iron-sulfur cluster scaffold homolog) patients have higher expression of FGF in muscle and higher FGF serum levels (), indicating some similarities between mice and humans. It further indicates that under extreme metabolic disarrangements, muscle might contribute to circulating FGF levels in mice and humans.
Mitochondrial diseases
Mitochondrial diseases represent a heterogeneous group of rare genetic and acquired metabolic disorders characterized by mitochondrial dysfunction [for review, see Magner et al. () ]. Several groups demonstrated markedly elevated FGF blood levels in mitochondrial diseases (, -). Although the molecular link is currently unclear, these findings are in line with increased FGF levels observed in common diseases associated with mitochondrial dysfunction, that is, insulin resistance, nonalcoholic fatty liver disease, myopathy, and TD (-).
Pancreatitis
One of the major FGF mRNA expression sites in mice is pancreas. Pancreatic FGF gene expression derives from endocrine a-and b-cells as well as exocrine acinar cells (, -). In the latter, FGF is induced in experimental models of pancreatitis in mice (, , ). In agreement, FGF is elevated in serum of patients with pancreatitis ().
Lipodystrophies
Patients with human immunodeficiency virusassociated, congenital, and acquired lipodystrophies, that is, pathologies characterized by reduced adipose tissue mass, marked ectopic lipid deposition, and insulin resistance demonstrate elevated FGF levels (, ).
FGF21 resistance
With respect to the beneficial effects of FGF on murine glucose and lipid metabolism, the elevated FGF blood concentrations observed in murine and human diseases with disturbed glucose and lipid metabolism are completely unexpected. This has prompted the hypothesis of FGF resistance, as it is comparable to high circulating insulin and leptin concentrations in insulin-and leptin-resistant states, respectively. Accordingly, treating diet-induced obese mice with recombinant human FGF leads to no significant decline in blood glucose concentrations and only a small decrease in plasma FFA concentrations together with attenuated ERK signaling and impaired induction of the FGF target genes early growth response- and c-Fos in liver and adipose tissue (, ). In agreement, human obesity is accompanied by elevated FGF levels and reduced levels of KLB in WAT (). A recent study demonstrated impaired FGF-induced ERK phosphorylation in WAT of obese mice, which could not be restored by maintaining KLB expression in WAT, indicating FGF resistance in WAT is downstream of KLB (). Murine studies further indicate that thiazolidinediones may increase KLB expression, thus potentially enhancing FGF signaling (), and recently it has been demonstrated that dietary fish oil increased hepatic FGF sensitivity by increasing KLB (). However, there are also mouse studies arguing against FGF resistance: Hale et al.
() tested HFD-fed obese and genetically obese ob/ob mice and found that even though WAT expression of KLB and FGFRc are reduced, dose-response curves with recombinant human FGF reveal no right-shifted ERK phosphorylation in liver or adipose tissue. Moreover, these obese animals were more responsive to glucose-and weight-lowering effects of FGF than were lean mice (). Whether these contradictory results derive from the different obesogenic diets or mouse strains used remains to be determined. More work is needed to prove or reject the hypothesis of FGF resistance in particular in human obesity and its associated metabolic complications.
In summary, any changes (physiological or pathophysiological) in metabolism (whole body or just tissue specific) are characterized by induction of FGF in mice and humans. Thus, FGF emerges as an energy (nutritional) stress-induced factor not only in liver (Fig. ) but also in muscle, BAT/WAT, and pancreas (Fig. ) . The contribution, however, of extrahepatic expression sites (adipose tissue and muscle) to circulating levels has only been suggested for some mouse models/conditions, and direct data in humans are missing. Furthermore, it is not known how certain conditions provoke FGF release from the tissue into the circulation whereas others do not.
Metabolic Effects of FGF21 in Mice and Humans
Effects on whole-body glucose and lipid metabolism Administration of (human or murine) recombinant FGF to nutritional (HFD-fed) or genetic (i.e., ob/ob and db/db) mouse models of obesity and diabetes increases fat utilization and energy expenditure and reduces body weight, whole-body fat mass, and liver triglyceride content (, , ). Furthermore, FGF administration provokes resistance to HFD-induced weight gain, improves glucose tolerance and hepatic and peripheral insulin sensitivity (without triggering hypoglycemia), and normalizes hyperinsulinemia and hypertriglyceridemia (, , ). In vivo, FGF-mediated glucose transporter  induction and glucose uptake in WAT is only seen in lean, but not in obese, mice, suggesting that the robust reduction in blood glucose concentration observed in acutely FGF-treated obese mouse models results from the indirect suppressive effect of FGF on hepatic glucose output (, , ). In the apolipoprotein E-deficient mouse model of atherosclerosis, FGF inhibits atherosclerotic plaque formation in part by suppressing hepatic expression of the transcription factor sterol regulatory element binding protein , thereby attenuating hepatic cholesterol synthesis and improving hypercholesterolemia (). Conversely, whole-body FGF deficiency due to genetic knockout promotes weight gain, hepatosteatosis, and glucose intolerance upon ketogenic diet (). The findings in mice about improvements in lipid and glucose metabolism prompted pharmaceutical companies around the world to develop FGF-based novel therapies for metabolic diseases, especially for TD.
Owing to the instability of recombinant nonglycosylated FGF in the circulation, for humans, only results with stabilized FGF analogs (LY and PF-) are available (-). LY represents a human FGF molecule modified by introduction of an additional disulfide bond, deletion of four N-terminal amino acids, and elimination of an O-linked glycosylation site (); PF- is an artificial macromolecule formed by covalent conjugation of two modified human FGF molecules (desHis FGF AlaCys) to the Fab regions of a monoclonal scaffold antibody (). LY was already tested in TD patients in a randomized placebo-controlled double-blind proof-of-concept trial ():  weeks of LY treatment reduced plasma triglycerides and total and LDL cholesterol concentrations and increased plasma high-density lipoprotein cholesterol, b-hydroxybutyrate, and serum adiponectin concentrations, but it did not reveal a significant effect on blood glucose levels. Similar effects on plasma lipids as well as a lack of effect on blood glucose were also observed for PF- after a single intravenous dose administered to TD patients (). Talukdar et al. () performed a -week randomized placebo-controlled phase b trial with twice-weekly administration of PF- ( to  mg) in TD patients and reported, apart from improvements in plasma lipids, significantly decreased body weight, increased blood adiponectin concentrations, reduced blood markers of bone formation, increased markers of bone resorption, elevated blood insulin-like growth factor (IGF)- levels, and no effect on plasma glucose upon treatment. Another study using once-weekly injection of PF- ( to  mg) in obese hypertriglyceridemic subjects reported reduced TG levels and increased adiponectin levels without changes in body weight, but again no improved glucose metabolism (). It is unclear whether the observed weight loss in the study of Talukdar et al. () is due to side effects, that is, diarrhea and nausea (seen in % and % of PF--treated patients, respectively) that may have impaired food intake. These human studies recapitulated the beneficial effects of FGF on lipid metabolism found in mouse studies, but they revealed one crucial deviation: FGF analogs failed to lower blood glucose in humans. Note Effects on growth and lifespan FGF transgenic mice are markedly smaller than their wild-type littermates (), and FGF causes hepatic GH resistance by blunting GH signaling at the extracellular and intracellular level (). Additionally, transgenic FGF overexpression extends lifespan of CBL/ mice by % by interfering with GH/IGF- signaling in liver without affecting food intake, physical activity, energy expenditure, or adenosine 9-monophosphate-activated protein kinase, mammalian target of rapamycin, and sirtuin signaling in liver, muscle, and adipose tissue (). Recently, it has been demonstrated that an increase in lifespan by FGF overexpression involves the prevention of ageinduced loss of naive T cells (). Given that these observations have been made with a mouse model that is hypermetabolic and growth-restricted due to transgenic overexpression of FGF, an effect of FGF on lifespan and growth in humans is very speculative. A study investigating the association of FGF and growth or IGF- in obese children revealed no connection (), contrasting another study demonstrating an inverse relationship of FGF with linear growth rate in infancy (). Thus, FGF as a negative regulator of human growth has not been established, but awaits further studies.
Effects on glucose and lipid metabolism mediated by adipose tissue As WAT has high FGFRc and KLB expression and the FGFRc/KLB complex is the preferred signaling complex for FGF, adipose tissue is considered the major target of FGF. In HFD-fed mice, adipose tissue-selective ablation of either KLB or FGFR impairs FGF effects, such as weight loss, insulin sensitization, and improvement of glucose tolerance, hyperinsulinemia, and hypertriglyceridemia (, , ). Additionally, the beneficial effects of FGF are absent in a mouse model of lipodystrophy but restored after WAT transplantation (), indicating a central role for WAT in mediating FGF improvements on whole-body metabolism.
It has become clear that FGF plays a role in WAT lipolysis, but there are conflicting reports on whether FGF promotes or inhibits lipolysis. In particular, cell culture experiments using FGF treatment or gain-and loss-of-function studies in human or murine primary adipocytes or murine T-L adipocytes demonstrated inconsistent results (-). In vivo studies suggest a difference between chronic vs acute effects: administration of a single dose of recombinant human FGF acutely lowered plasma FFA concentrations and WAT hormone-sensitive lipase expression in lean and ob/ob mice (, ). In contrast, mouse models with chronically altered FGF levels (knockout, overexpression, and FGF administration) support the lipolysis-promoting effect of FGF with increased expression of lipases (hormone-sensitive lipase, adipose triglyceride lipase), reduced adipocyte size, and elevated plasma FFA concentrations (, , ). This argues for a more indirect and context-dependent effect of FGF on WAT lipolysis, which might also explain inconsistent cell culture results using different conditions. Recent mouse data indicate that inflammation (e.g., mediated by interleukin-) might affect FGF-mediated lipolysis (), which is commonly observed in obesity and its associated metabolic disorders.
FGF acutely affects the production and release of the adipocyte-derived hormone (adipokine) adiponectin: a single FGF dose doubles adiponectin concentration in the blood (). Adiponectin is an insulin-sensitizing, anti-inflammatory, and atheroprotective adipokine with a major role in glucose and lipid metabolism (, ). When adiponectin is genetically ablated, HFD-induced and genetic mouse models of obesity are refractory to FGF-induced improvements in hyperglycemia, hypertriglyceridemia, hepatic and muscle insulin resistance, and hepatosteatosis (, ). Of note, the protective function of FGF on vascular inflammation and atherosclerotic plaque formation in apolipoprotein E-deficient mice is at least in part dependent on its adiponectin-elevating properties (). In humans, administration of the FGF analog LY or PF- led to increased adiponectin levels in obese/diabetic patients (, , ), indicating that also human metabolism might benefit indirectly from FGF administration by increased adiponectin levels.
FGF stimulates glucose uptake in murine and human adipocytes (), and Ge et al. () demonstrated that this is due to transcriptional activation of the glucose transporter  gene via ERK/, serum response factor, and Ets-like protein-. FGF effects on glucose uptake are more pronounced in BAT: in vivo, injecting native FGF into diet-induced obese mice increased glucose uptake in WAT but to a much higher extent in BAT (, ), and mice having no circulating FGF (liver-specific FGF knockout mice) show reduced glucose uptake specifically in BAT, not WAT, muscle or heart ().
Schlein et al. () reported that WAT and BAT contribute to FGF-stimulated reductions in plasma triglyceride concentrations by enhanced "There is uncertainty whether FGF21-induced adipose tissue browning is exclusively a direct effect on adipocytes."
clearance of triglyceride-rich lipoproteins in these depots. Additionally, Coskun et al. () reported that chronic FGF administration in obese mouse models (HFD-fed and ob/ob mice) reduces body weight and adiposity via increased energy expenditure and fat utilization, suggesting the involvement of BAT (and/or browning of WAT) in these fat mass-regulating FGF effects. Adipose tissue browning (conversion of white adipocytes into brown-like UCP-positive cells) () depends, at least in part, on FGF, as FGF-deficient mice display significantly diminished browning capacity (). Furthermore, chronic FGF treatment and FGF gene transfer to the mouse liver are accompanied by induction of thermogenic genes (e.g., UCP) and of genes favoring b-oxidation of fatty acids (e.g., carnitine palmitoyltransferase-a and -b) in BAT (, , ). Finally, induced hepatic FGF production may also be involved in activation of thermogenesis during the fetal-to-neonatal transition, a critical period where newborns have to compensate for a dramatic drop in ambient temperature (). There is uncertainty whether FGF-induced adipose tissue browning is exclusively a direct effect on adipocytes: recent evidence, based on central KLB knockout and lateral ventricle infusion of FGF, suggests that hypothalamic FGF signaling stimulating sympathetic nerve activity contributes to adipose tissue browning (, ). Of note, two studies support the notion that pharmacological FGF effects are independent of WAT browning (, ). Although there seems to be a connection between FGF and BAT in humans as well (), the rather low capacity for browning and the low amount of BAT in humans (usually at thermoneutrality) as compared with mice (commonly housed not at thermoneutrality) might explain at least partly the differences of the effects of FGF on glucose metabolism between the two species.
Effects on glucose and lipid metabolism mediated by liver Among the earliest findings about FGF effects in mice was the stimulation of hepatic fatty acid oxidation (via induction of PPARg coactivator-a and -b) and ketogenesis (via induction of ketone body-synthesizing enzymes) in the fasting state and under fasting state-mimicking conditions (ketogenic diets) (, ). Additionally, FGF suppresses hepatic de novo lipogenesis (via repression of the lipogenic genes encoding sterol regulatory element-binding protein c and fatty acid synthase) (, , ). Thus, FGF transgenic mice display decreased hepatic triglyceride contents (), and FGF knockout mice store fatty acids from fasting-associated adipose tissue lipolysis as triglycerides in the liver (, ).
Chronic FGF treatment led to increased Akt phosphorylation, decreased diacylglycerol concentrations, and reduced protein kinase C« activity in liver specimens, indicating insulin sensitization at the hepatocellular level (, ). In agreement, FGF knockout mice demonstrate hepatic insulin resistance and elevated hepatic glucose production (). Data obtained from liverspecific insulin receptor knockout mice demonstrate that FGF effects on glucose metabolism are not due to direct effects on liver but to activation of BAT and browning of WAT, leading to increased energy metabolism and substrate use (). These data further suggest that insulin action in the liver is not required for FGF to correct hyperglycemia but to mediate its effect on lipid metabolism in diabetic mice ().
Berglund et al. () and Xu et al. () demonstrated that chronic FGF treatment suppressed hepatic glucose output and enhanced hepatic glycogen storage. In contrast, transgenic FGF mice demonstrated enhanced gluconeogenesis already during the fed state, and acute FGF treatment leads to PPARg coactivator-a-independent induction of the key gluconeogenic enzymes glucose--phosphatase and phosphoenol pyruvate carboxykinase, reflecting the prominent role of FGF during fasting (, ).
However, a direct effect of FGF on liver in vivo has been questioned, as FGFR is the main FGF receptor isoform expressed in liver and FGF does not activate downstream signaling through the FGFR/KLB complex (no phosphorylation of ERK) (). Besides indirect effects of FGF on liver, another explanation for a more direct FGF effect on liver has recently been proposed: FGF antagonizes the effect of FGF/ on the hepatic FGFR/KLB complex, thereby increasing the bile acid pool (). Several studies on FGF effects on human liver used HepG cells as a model for hepatocytes, but in contrast to primary hepatocytes, HepG cells do express high amounts of FGFRc, and therefore these data cannot be extrapolated into the human in vivo context. Nevertheless, human and murine liver do express FGFRc, although to a much lower degree than adipose tissue, and hepatic FGFRc expression is even higher than in adipose tissue (). Notably, the regulating effect of FGF on cholesterol metabolisms has been suggested to be at least partly mediated via the FGFR/KLB complex in the liver (), and FGFR is the second most abundant FGFR isoform in liver ().
Effects on pancreas
Pancreatic acinar and islet cells are FGF targets, and FGF treatment triggers ERK signaling in both cell types (). Wente et al. () demonstrated that shortterm FGF treatment of healthy CBL/ mice and diabetic db/db mice lowers blood insulin concentrations after an oral glucose load. In contrast, constant long-term infusion of FGF in db/db mice raises insulin (). In the absence of enhanced islet cell proliferation, long-term treatment provokes increments in pancreatic islet number and insulin content per islet (). FGF knockout mice display distortion of islet morphology and impaired glucose-stimulated insulin secretion, with the latter possibly due to unblocked GH signaling in the islets (). Moreover, HFD-fed FGF-deficient mice develop islet hyperplasia and periductal lymphocytic inflammation (). Notably, FGF has recently been discovered as a pancreatic secretagogue that mainly functions in an autocrine/paracrine manner to alleviate ER stress that can occur in pancreas under either physiological conditions such as fasting/refeeding or pathological conditions such as pancreatitis (). Collectively, these findings point to islet-protective functions of FGF. Interestingly, hyperglycemia in db/db mice and high glucose concentrations in vitro downregulate KLB expression and FGF signaling in pancreatic islets, providing preliminary evidence of hyperglycemiainduced FGF resistance in the pancreas of diabetic mice (). No published in vivo data on FGF expression or direct action on human pancreas are available.
Effects on brain
Very recently, it was demonstrated that FGF is expressed in different murine brain regions, including substantia nigra and striatum (), and in cerebellar neurons upon treatment with cell adhesion molecule L (). FGF expression in the brain in mice and most importantly in humans still needs further confirmation, and so far nothing is known about potential regulatory stimuli or mechanisms. Notably, however, FGF is able to pass the murine blood-brain barrier () and this seems to be true also for humans (). In the brain of CBL/ mice, FGFRc and FGFRc, the two major FGFRs, are broadly expressed, whereas KLB expression is restricted to the suprachiasmatic nucleus of the hypothalamus, where the circadian pacemaker is located, and the dorsal vagal complex and nodose ganglia of the hindbrain (). FGF action in the murine brain via KLB increases corticosterone levels, lowers insulin levels, inhibits growth, and alters circadian rhythm, all representing features of starvation (, ). Additionally, central FGF action is needed for its effect on energy expenditure (via WAT browning), weight loss, and lowering cholesterol in mouse models (, , , ). 
Effects on bone
The negative regulation of bones by FGF is one of the adverse effects that may jeopardize the use of FGF as a therapeutic (, ). Even though the presence of KLB in osteoblasts and/or osteoclasts remains to be proven, FGF has effects on bones: using transgenic overexpression and pharmacological application of FGF, Wei et al. () reported striking decreases in bone mass together with ex vivo assay data demonstrating inhibition of osteoblastogenesis and stimulation of adipogenesis in bone marrow-derived mesenchymal stem cells by FGF. In contrast, FGF knockout mice exhibit a high-bone mass phenotype () and are protected from transient loss of bone mass during lactation (). Even though FGF has no direct impact on osteoclasts, it promotes IGF-binding protein- release from liver, and IGF-binding protein- stimulates bone resorption in vivo (). Thus, FGF promotes bone loss via direct inhibition of bone formation and indirect enhancement of bone resorption. In humans, the FGF analog PF- leads to changes in bone biomarkers with body weight changes () but also without body weight changes (). Thus, adverse effects on bones need to be carefully addressed in future human studies.
Figure  summarizes effects (chronic and acute) of regular, that is, wild-type, FGF on metabolically relevant tissues/organs in mice and humans as derived from treatment studies and, for mice, from genetic manipulation as well: in brief, very similar FGF effects on lipid and glucose metabolism are reported in the two species with respect to adipocyte glucose uptake and mitochondrial oxidative capacity, fat cell browning, as well as hepatic fatty acid oxidation and de novo lipogenesis. However, obvious differences exist between mice and humans when looking closer at the effects of FGF on adipocyte lipolysis and hepatic ketogenesis. BAT seems to be the major tissue mediating FGF effects on glucose uptake, and this might represent the reason for the missing effect of FGF on glucose in obese patients, which have only low or even no BAT (, ).
Human Genetic Data
In line with a potential role of FGFR-KLB signaling in liver being responsible for FGF effects on cholesterol metabolism (), a genetic variant of FGFR [single nucleotide polymorphism (SNP) rs] is associated with LDL cholesterol in humans (). Consistent with a potential role of FGF in the brain, as proposed by mouse data, two large genome-wide association studies provided evidence that SNPs in or near the human FGF gene modulate macronutrient intake in humans independently of BMI: minor allele carriers of the synonymous SNP rs in exon  of the FGF gene exhibit reduced energy intake from protein and increased energy intake from carbohydrates (); and the minor allele of SNP rs,~ kb upstream of the FGF gene and in moderate linkage disequilibrium with rs (r  = .), is associated with higher energy intake from carbohydrates, lower energy intake from fat, and higher circulating FGF concentrations (). The SNP rs has recently been associated not only with sugar preference but also with more consumption of alcohol and tobacco, thus other forms of rewardseeking behavior. Interestingly, variations in KLB, the obligate FGF coreceptor, have also been identified to be associated with alcohol drinking in humans (). Even though functional data on how the SNPs alter FGF function/expression are lacking, these data suggest that genetic variation in the FGF gene and its receptor determines nutrient choices in humans by acting on the reward system.
Summary and Conclusions
FGF represents a fascinating hormone with impressive implications in whole-body homeostasis and several metabolically relevant pathways, in particular in lipid and glucose metabolism in both mice and humans. This is why most published work hitherto was primarily driven by pharmacological interests and not by academic interests in this hormone's role in physiology and pathophysiology. Since , the year of its discovery, FGF has been intensely studied in mice, and a wealth of very robust data has been generated in mice that, with the exception of a negative impact on bone metabolism, consistently documents favorable roles of FGF in lipid and glucose metabolism. The last  years of in vivo and ex vivo analyses in humans have also created a considerable body of data complicating the translation of several of the mouse findings to the human situation. Human treatment studies assessing the systemic effects of regular FGF are currently lacking due to the instability of recombinant nonglycosylated FGF in the circulation, but results from three treatment studies using FGF analogs are available (- Based on all what is hitherto known about FGF, it is insufficient to explain the observed discrepancies of the pharmacological effect of FGF analogs on blood glucose between mice and humans merely by limited availability of human data or by the ultimately unproven existence of FGF resistance. Rather, it is more obvious that the differences have species-specific reasons and derive from technical limitations associated with the use of mice as model organism for human physiology and disease. As species-inherent limitations, divergences due to adaptations of mice and humans to their specific habitats, dietary habits, and environmental constraints are conceivable. With regard to metabolism, it is well known that mice considerably differ from humans in lipoprotein metabolism and susceptibility to atherosclerosis () as well as in inflammatory responses to different traumata (). A possible technical limitation of mouse studies may arise from housing temperatures that exert dramatic effects on inflammatory and atherosclerotic events () and BAT/WAT biology. As BAT and WAT are major targets of the beneficial effects of FGF on metabolism, we assume that this is the reason for the divergent findings between mice and humans in particular on glucose metabolism. In agreement, it has been shown in a mouse model that the glucose lowering effect of FGF is blunted when KLB is specifically ablated in UCP + cells (). There is no beneficial effect of FGF on glucose clearance in UCP-deficient mice (), and UCP knockout mice treated with FGF-Fc (another long-acting FGF analog) demonstrated no reduction in plasma glucose (). The relative small and varying amount of UCP + cells in humans may explain the divergent effect of FGF on glucose metabolism in mice and humans.
We stress that the vast majority of human in vivo data are of a correlational nature. If correctly adjusted for known confounders, these data can help unmask real relationships. However, we note that correlational data cannot give mechanistic insights or solve the problem of causation/reverse causation (the "hen and egg" problem) inherent to all association analyses. Additionally, only very few FGF treatment studies that harbor the potential to provide mechanistic clues have hitherto been reported in humans. Apart from these limitations, an interesting observation is the robust positive correlation of FGF levels with many human metabolic disorders and diseases, for example, metabolically unhealthy obesity, nonalcoholic hepatosteatosis, gestational diabetes, and TD, coronary artery/heart disease, preeclampsia, myopathy, lipodystrophy, and mitochondrial disease. Although FGF as an antidiabetic drug may not be feasible in humans, FGF might be a good biomarker and/or predictor for musclerelated mitochondrial diseases (, ) or arteriosclerosis ().
We should not abandon further exploration of the biology of FGF, but follow-up investigations are required to ultimately solve the FGF puzzle. Given the prominent role of FGF in lipid metabolism in mice and humans, patients suffering from metabolic disorders other than diabetes, such as atherosclerosis, might benefit from FGF therapies (). However, future studies need to carefully address issues such as the kind (e.g., murine vs human recombinant FGF), dose, and timing of FGF treatment. Perhaps new animal models closer to humans, for example, omnivores such as (mini)pigs, will provide functional and mechanistic data that can better be translated to the human situation. With respect to the emerging role of the brain in metabolic diseases (-), one of the most exciting and also most challenging areas of future research is certainly the assessment of the efficacy of FGF and its analogs in the brain.
